← All articles

K.C. Pharmaceuticals Recalls 3.1 Million Bottles Over Sterility Issues

K.C. Pharmaceuticals recalled over 3.1 million bottles of eye drops from eight brand names due to sterility concerns. The FDA assigned a Class II designation on March 31. The Dry Eye Relief formula accounted for more than one million bottles of the recalled inventory, with products distributed through major retail chains nationwide.

AI-assisted reporting

The essentials

K.C. Pharmaceuticals recalls 3.1 million eye drop bottles across eight brands for sterility issues.

K.C. Pharmaceuticals, based in Pomona, California, has initiated a recall affecting over 3.1 million bottles of eye drops due to sterility concerns. The FDA assigned a Class II designation to the recall on March 31, indicating a serious health risk that could cause adverse effects.

The recalled products were sold under eight brand names through major retail chains across the nation. Among the affected batches, the Dry Eye Relief formula represents the largest recalled quantity, exceeding one million bottles. The scope of distribution through multiple retail outlets underscores the widespread availability of the affected products.

Class II recalls require manufacturers to notify healthcare providers and the public, and retailers to remove products from shelves. The sterility classification suggests potential contamination risks that could compromise eye safety.

Broaden the view

Other ways to read this story.

Alternative framings generated by SigNews. These are not independent sources or attributed quotations.

Scope

Recall Extends Across Eight Brands and Major Retailers Nationwide

The recall's magnitude spans eight different brand names distributed through major retail chains nationwide. This broad distribution footprint means the affected eye drops reached consumers across multiple store locations. Over 3.1 million bottles were subject to the recall, with the Dry Eye Relief formula exceeding one million units, indicating substantial market penetration of the contaminated products.

Regulatory Action

FDA Class II Designation Signals Serious Health Risk Classification

The FDA's Class II designation on March 31 reflects the agency's assessment of serious potential health consequences from the sterility concerns. This classification triggers mandatory manufacturer notification, healthcare provider alerts, and retail removal requirements. The designation demonstrates regulatory attention to the contamination risk and establishes legal obligations for product withdrawal and consumer communication.